Catharanthine

• UNSPSC Description:

  Catharanthine ((+)-3,4-Didehydrocoronaridine), a constituent of anticancer vinca alkaloids, inhibits voltage-operated L-type Ca2+ channel (VOCC). Catharanthine has IC50s of 220 μM and 8 μM for VOCC currents in cardiomyocytes and vascular smooth muscle cells (VSMCs), respectively. Catharanthine lowers blood pressure (BP), heart rate (HR). Catharanthine has anti-cancer activity[1][2].

• Target Antigen:

  Calcium Channel

• Type:

  Natural Products

• Related Pathways:

  Membrane Transporter/Ion Channel;Neuronal Signaling

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer; Neurological Disease; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/catharanthine.html

• Purity:

  99.65

• Solubility:

  DMSO : ≥ 100 mg/mL|H2O : < 0.1 mg/mL (ultrasonic)

• Smiles:

  O=C([C@@]12C3=C(CC[N@](C4)[C@]1([H])C(CC)=C[C@@]4([H])C2)C5=CC=CC=C5N3)OC

• Molecular Weight:

  336.43

• References & Citations:

  [1]Jadhav A, et al. Catharanthine dilates small mesenteric arteries and decreases heart rate and cardiac contractility by inhibition of voltage-operated calcium channels on vascular smooth muscle cells and cardiomyocytes. J Pharmacol Exp Ther. 2013 Jun;345(3):383-92.|[2]Hugo R Arias, et al. (+)-Catharanthine and (-)-18-methoxycoronaridine induce antidepressant-like activity in mice by differently recruiting serotonergic and norepinephrinergic neurotransmission. Eur J Pharmacol. 2023 Jan 15:939:175454.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  2468-21-5